Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.

Buckell J. et al, (2023), Sci Rep, 13

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.

Wei J. et al, (2023), Nat Commun, 14

Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Supplementary Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Supplementary Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.

Emmenegger M. et al, (2023), iScience

Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom.

Vihta KD. et al, (2022), Clin Infect Dis, 75, e329 - e337

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.

Wei J. et al, (2022), Nat Commun, 13

Automated 96-well format high throughput colony formation assay for siRNA library screen.

Hatch SB. et al, (2022), STAR Protoc, 3

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.

Wei J. et al, (2022), Nat Med, 28, 1072 - 1082

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Small molecule screen employing patient-derived iPSC hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency

Kent D. et al, (2022)

CHK1 inhibition exacerbates replication stress induced by IGF blockade.

Wu X. et al, (2022), Oncogene, 41, 476 - 488

Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom.

Walker AS. et al, (2021), N Engl J Med, 385, 2582 - 2585

Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs

Arnaiz E. et al, (2021), BMC Cancer, 21

Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Writing Committee for the REMAP-CAP Investigators None. et al, (2021), JAMA, 326, 1690 - 1702

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.

Wei J. et al, (2021), Nat Commun, 12

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.

Lumley SF. et al, (2021), Clin Infect Dis, 73, e699 - e709

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections.

Eyre DW. et al, (2021), BMC Infect Dis, 21

Load More

Include forthcoming?